These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17680022)

  • 1. Pharmacokinetics of melphalan in myeloma patients undergoing an autograft.
    Nath CE; Shaw PJ; Trotman J; Zeng L
    Bone Marrow Transplant; 2007 Oct; 40(7):707-8. PubMed ID: 17680022
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engraftment syndrome after hematopoietic stem cell transplantation in multiple myeloma.
    Katzel JA; Mazumder A; Jagannath S; Vesole DH
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):151. PubMed ID: 17026829
    [No Abstract]   [Full Text] [Related]  

  • 4. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later.
    Lazarus HM; Phillips GL; Herzig RH; Hurd DD; Wolff SN; Herzig GP
    J Clin Oncol; 2008 May; 26(14):2240-3. PubMed ID: 18467711
    [No Abstract]   [Full Text] [Related]  

  • 6. Autologous hematopoietic stem-cell transplantation for multiple myeloma.
    Harousseau JL; Moreau P
    N Engl J Med; 2009 Jun; 360(25):2645-54. PubMed ID: 19535803
    [No Abstract]   [Full Text] [Related]  

  • 7. Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant.
    Radujkovic A; Hundemer M; Eisenbach C; Luft T; Penzel R; Goldschmidt H; Ho AD; Bellos F
    Leuk Lymphoma; 2014 Dec; 55(12):2967-9. PubMed ID: 24707945
    [No Abstract]   [Full Text] [Related]  

  • 8. Allografting or autografting for myeloma.
    Rajkumar SV; Kyle RA
    N Engl J Med; 2007 Jun; 356(25):2646-8; author reply 2646-8. PubMed ID: 17600891
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of multiple myeloma: the changing landscape.
    Reece DE
    Blood Rev; 2007 Nov; 21(6):301-14. PubMed ID: 17761373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of newly diagnosed myeloma.
    Rajkumar SV; Palumbo A
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1141-56, ix-x. PubMed ID: 17996592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy of multiple myeloma: melphalan--40 years old and still going strong.
    Bergsagel PL
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):2-3. PubMed ID: 12533738
    [No Abstract]   [Full Text] [Related]  

  • 12. A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.
    Giglia JL; White MJ; Hart AJ; Toro JJ; Freytes CO; Holt CC; Cai Y; Williams SM; Brandt SJ
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):1014-20. PubMed ID: 24704384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
    Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
    Qazilbash MH; Saliba RM; Nieto Y; Parikh G; Pelosini M; Khan FB; Jones RB; Hosing C; Mendoza F; Weber DM; Wang M; Popat U; Alousi A; Anderlini P; Champlin RE; Giralt S
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1401-7. PubMed ID: 19041063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
    Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Autologous stem cell transplantation in multiple myeloma - pro].
    Goldschmidt H
    Dtsch Med Wochenschr; 2009 Sep; 134(39):1942. PubMed ID: 19760555
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of transplant in multiple myeloma.
    Barlogie B
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):604-6. PubMed ID: 16167043
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased pulmonary toxicity results from a 1-day versus 2-day schedule of administration of high-dose melphalan.
    Williams L; Beveridge RA; Rifkin RM; Bretzel RL; Cuasay L; Alley JL; McGuirk J
    Biol Blood Marrow Transplant; 2002; 8(6):334-5. PubMed ID: 12108919
    [No Abstract]   [Full Text] [Related]  

  • 19. Current status of autologous hematopoietic stem cell transplantation in myeloma.
    Mehta J; Singhal S
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S28-S34. PubMed ID: 18724294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melphalan-Induced Atrial Fibrillation.
    Shah AJ; Kobrossi S; Desai A
    Am J Ther; 2018; 25(5):e571-e572. PubMed ID: 28816723
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.